Biotech Values

[jaybe]

I agree, at this point convincing case needs head-to-head trial.

There's an IST (Spirit3) enrolling in January at 30mg dose, 2nd line "early switch", head-to-head against nilotinib, 500 patients each arm. Of course this assumes early switch becomes standard practice, but NVS, BMS, and PFE are helping to make the case. http://spirit3.spirit-cml.org/

What do you think about another front line possibility, using Pona at 30mg to reach MMR as quickly as possible and then generic imatinib as maintenance? Avoids VTE issue and has to be most cost effective.